NeuroEM Therapeutics, Inc.

11:30 AM - 11:45 AM (PDT), Tuesday, June 14, 2022

NeuroEM is a clinical-stage company that has received FDA "Breakthrough" designation for its wearable MemorEM device for the treatment of cognitive decline in patients with Alzheimer's Disease. MemorEM delivers Transcranial Electromagnetic treatment, ("TEMT")
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Arizona
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
MemorEM therapeutic device
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
Chairman, Corporate Development Advisory Board
NeuroEM Therapeutics, Inc.